Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Inks Alliance with Agios Pharmaceuticals

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed two agreements with cancer startup Agios Pharmaceuticals related to its X-Man cell-line technology.
 
The Cambridge, UK-based firm said that it has licensed certain X-Man cell lines, including major cancer-causing genes and their matched normal genetic backgrounds. In addition, it said that it would screen a number of Agios lead compounds on a wide panel of genotypes.
 
Horizon said that its technology should enable Agios to understand how key oncogenic pathways of cancer cells survive in tumors and to predict the genomic makeup of tumors in the responsive patient types.
 
Cambridge, Mass.-based Agios will pay Horizon undisclosed up-front and renewal fees during the term of the agreements. They expect to begin the collaboration this month.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.